Bill Text: HI HB254 | 2016 | Regular Session | Amended
Bill Title: Biosimilar Medicines; Interchangeable Biological Products; Hawaii List of Equivalent Generic Drug Products and Interchangeable Biological Products; Director of Health
Spectrum: Partisan Bill (Democrat 4-0)
Status: (Passed) 2016-07-13 - Act 242, on 07/12/2016 (Gov. Msg. No. 1351). [HB254 Detail]
Download: Hawaii-2016-HB254-Amended.html
|
HOUSE OF REPRESENTATIVES |
H.B. NO. |
254 |
|
TWENTY-EIGHTH LEGISLATURE, 2015 |
H.D. 1 |
|
|
STATE OF HAWAII |
|
|
|
|
|
|
|
|
||
|
|
||
A BILL FOR AN ACT
RELATING TO MEDICINES.
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
SECTION 1. The legislature finds that biologics are a class of medicines available to treat disease. Unlike traditional drugs, which are chemically manufactured, biologics are manufactured in living cells. Common biologics in use today include human growth hormone, injectable treatments for arthritis and psoriasis, the Hepatitis B vaccine, and stem cell therapy.
The term "biosimilars" refers to substitute versions of brand-name biologics, similar to generic versions of brand-name drugs. These substitutes are not exactly identical to brand-name biologics but are designed to provide commensurate benefits to patients at lower costs. At least nineteen biosimilars are currently approved for use in the European Union.
The Patient Protection and Affordable Care Act, signed into law by President Barack Obama in 2010, created an abbreviated licensure pathway for biological products that are demonstrated to be biosimilar to or interchangeable with a biologic product licensed by the United States Food and Drug Administration (FDA). In early 2015, the FDA approved its first biosimilar drug, Zarxio for use in the United States. Zarxio is used to help prevent infections in cancer patients receiving chemotherapy and is a close copy of an existing medication called Neupogen. Market research reports that there are at least one hundred fifty biosimilars in development.
As of September 15, 2015, sixteen states and Puerto Rico have passed legislation to regulate the substitution of biosimilars for brand-name biologics by pharmacists, and at least thirty-one states have considered similar legislation. Other important issues relating to state regulation of biosimilars include the powers and duties of prescribing authorities, notice to patients, safety, and recordkeeping.
The purpose of this Act is to allow for the regulation of biosimilar medicines to ensure patient safety and access to medicines at lower prices.
SECTION 2. Section 328-16, Hawaii Revised Statutes, is amended by amending subsection (a) to read as follows:
"(a) A prescription drug shall be dispensed only if its label bears the following:
(1) The name, business address, and telephone number of the seller. The business address shall be the physical location of the pharmacy or the dispensing practitioner's office;
(2) Except as otherwise authorized for expedited partner therapy in section 453-52, the name of the person for whom the drug was prescribed or the name of the owner of the animal for which the drug was prescribed;
(3) The serial number of the prescription;
(4) The date the prescription was prepared;
(5) The name of the practitioner if the seller is not the practitioner;
(6) The name, strength, and quantity of the drug;
(7) The "use by" date for the drug, which shall be:
(A) The expiration date on the manufacturer's container; or
(B) One year from the date the drug is dispensed,
whichever is earlier;
(8) The number of refills available, if any;
(9) In the case of the dispensing of an equivalent
generic drug product, the statement "same as (brand name of the drug
product prescribed or the referenced listed drug name)", or words of
similar meaning; [and]
(10) In the case of the dispensing of an interchangeable drug product, the statement "interchangeable with (brand name of the drug product prescribed or the referenced listed drug name)", or words of similar meaning; and
[(10)] (11) Specific directions for the
drug's use; provided that if the specific directions for use are too lengthy
for inclusion on the label, the notation "take according to written
instructions" may be used if separate written instructions for use are
actually issued with the drug by the practitioner or the pharmacist, but in no
event shall the notation "take as directed", referring to oral
instructions, be considered acceptable.
If any prescription for a drug does not indicate the number of times it may be refilled, if any, the pharmacist shall not refill that prescription unless subsequently authorized to do so by the practitioner. The act of dispensing a prescription drug other than a professional sample or medical oxygen contrary to this subsection shall be deemed to be an act that results in a drug being misbranded while held for sale."
SECTION 3. Section 328-91, Hawaii Revised Statutes, is amended as follows:
1. By adding three new definitions to be appropriately inserted and to read:
""Biological product" has the same meaning as defined in Title 42 United States Code section 262.
"Drug product" means a drug as defined in section 328-1 other than a biological product as defined in this part.
"Interchangeable biological product" means a biological product that the United States Food and Drug Administration:
(1) Has licensed and has determined meets the standards for interchangeability pursuant to Title 42 United States Code section 262(k)(4); or
(2) Has determined is therapeutically equivalent as set forth in the latest edition of, or supplement to, the United States Food and Drug Administration's "Approved Drug Products with Therapeutic Equivalence Evaluations"."
2. By amending the definition of "compendia of therapeutically equivalent generic drugs" to read:
""Compendia of therapeutically
equivalent generic [drug] drugs and interchangeable biological
products" means:
(1) For
a "drug product", the Orange Book and any United States Food and
Drug Administration documentation of any United States Food and Drug
Administration-approved generic drug product with therapeutic equivalency [evaluations],
including [but not limited to]:
[(1)] (A)
Letters of approval of Abbreviated New Drug Applications with therapeutic
equivalency evaluations;
[(2)] (B)
Published listings of approved New Drug Applications or approved Abbreviated
New Drug Applications with therapeutic equivalency evaluations; and
[(3)] (C)
Listings of first time generics with therapeutic equivalency evaluations,
adopted by the [director.] board;
(2) For a "biological product", approved under the Public Health Service Act, the Purple Book, and any United States Food and Drug Administration documentation of any United States Food and Drug Administration-approved interchangeability determination, including:
(A) Letters of approval of Biologic Licensing Application with a determination that the biological product meets the criteria for interchangeability as set forth in Title 42 United States Code section 262(k)(4); and
(B) Published listings of approved Biologic Licensing Applications with a determination that the biological product meets the criteria for interchangeability as set forth in Title 42 United States Code section 262(k)(4); and
(3) For a "biological product", approved under the Federal Food, Drug, and Cosmetic Act; the Orange Book; and any United States Food and Drug Administration documentation of any United States Food and Drug Administration-approved Interchangeability determination, including:
(A) Letters of approval of approved New Drug Applications or approved Abbreviated New Drug Applications with therapeutic equivalency evaluations; and
(B) Published listings of approved New Drug Applications or approved Abbreviated New Drug Applications with therapeutic equivalency evaluations."
3. By amending the definition of "savings" to read:
""Savings" means the financial benefit derived from utilizing the substituted equivalent generic drug product or interchangeable biological product from the perspective of the consumer or the ultimate payer, including third party payers."
SECTION 4. Section 328-92, Hawaii Revised Statutes, is amended to read as follows:
"§328-92 Drug product and interchangeable biological product selection. (a) When filling a prescription order for a drug prescribed by its brand name, a pharmacist or the pharmacist's authorized agent shall:
(1) Offer to the consumer an equivalent generic drug product or an interchangeable biological product from the formulary adopted pursuant to section 328-96; and
(2) Upon the request of the consumer, inform the consumer of the savings; and
(3) Inform the consumer of the consumer's right to refuse substitution.
The pharmacist shall substitute an equivalent generic drug product or an interchangeable biological product if the practitioner does not prohibit substitution under subsection (b), and the substitute equivalent generic drug product or interchangeable biological product results in a savings. The pharmacist shall not substitute if the consumer refuses.
(b) The pharmacist shall not substitute an equivalent generic drug product or an interchangeable biological product if the practitioner indicates "brand medically necessary" or words of similar meaning on the prescription. The designation "brand medically necessary" or other similar words or phrases must be handwritten by the practitioner and shall not be preprinted or stamped on the written prescription. The pharmacist shall not substitute an equivalent generic drug product or an interchangeable biological product if a prescription is orally or electronically ordered and the practitioner or authorized employee of the practitioner indicates "brand medically necessary" or other similar words or phrases.
The pharmacist shall note the practitioner's instructions on the prescription record required to be maintained under section 328-17.7.
This subsection shall not apply when it does not comply with any federal requirement for services reimbursable by medicaid or medicare.
(c) The pharmacist shall not substitute an equivalent generic drug product or an interchangeable biological product for any prescription for an anti-epileptic drug, except upon the consent of the practitioner and the patient or the patient's parent or guardian. This narrow exception for epileptic patients shall not be construed as a policy decision to make exceptions for any other conditions.
(d) Within five business days following the dispensing of a biological product, the dispensing pharmacist or the pharmacist's designee shall communicate the specific product provided to the patient, including the name of the product and the manufacturer. The communication shall be conveyed by making an entry that is electronically accessible to the prescriber through:
(1) An interoperable electronic medical records system;
(2) An electronic prescribing technology;
(3) A pharmacy benefit management system; or
(4) A pharmacy record.
(e) Entry into an electronic records system as described in subsection (d) is presumed to provide notice to the prescriber. Otherwise, the pharmacist shall communicate the biological product dispensed to the prescriber using facsimile, telephone, electronic transmission, or other prevailing means, provided that communication shall not be required where:
(1) There is no approved interchangeable biological product approved by the United States Food and Drug Administration for the product prescribed; or
(2) A refill prescription is not changed from the product dispensed on the prior filling of the prescription.
[(d)] (f) The county
prosecutors and the attorney general may bring action upon complaint by an
aggrieved person or upon their own motion in the name of the State against any
person to enjoin any violation of this part."
SECTION 5. Section 328-94, Hawaii Revised Statutes, is amended to read as follows:
"§328-94 Prescription record. Each pharmacist or practitioner shall maintain a record of any substitution of an equivalent generic drug product or an interchangeable biological product for a prescribed brand name drug product as provided in this part."
SECTION 6. Section 328-96, Hawaii Revised Statutes, is amended to read as follows:
"§328-96 Drug formulary; Hawaii
additions and deletions list. (a) The board may adopt rules, pursuant to chapter
91, to effectuate the purpose of this part. Without regard to chapter 91, the
director may adopt as rules the compendia of therapeutically equivalent generic
drug products and interchangeable biological products as the state drug
formulary of equivalent multiple source drug products[.] and
interchangeable biological products. The board may adopt rules pursuant to
chapter 91 to establish a Hawaii additions and deletions list[.];
provided that section 328-92(c) shall apply, and no pharmacist shall substitute
an equivalent generic drug product or an interchangeable biological product for
any prescription for an anti-epileptic drug to treat epilepsy, except upon the
consent of the practitioner and the patient or the patient's parent or
guardian. Upon the adoption of the compendia of therapeutically equivalent
generic [drug] drugs and interchangeable biological products by
the [director,] board, the [department] board shall
notify all pharmacies in the State and other interested individuals, within
thirty working days, that the formulary has been updated. The Hawaii additions
and deletions list may list additional substitutable drug products that are
determined by the board to be safe, effective, and therapeutically equivalent. The Hawaii additions and deletions list may not
include as substitutable any biologic products that the United States Food and
Drug Administration has not either licensed and determined meet the standards
for interchangeability pursuant to Title 42 United States Code section 262(k)(4)
or determined are therapeutically equivalent as set forth in the latest edition
of or supplement to the United States Food and Drug Administration's approved
drug products with therapeutic equivalence evaluations. The Hawaii
additions and deletions list may delete drug products listed in the compendia
of therapeutically equivalent generic [drug] drugs and interchangeable
biological products upon the board's finding that product quality or
therapeutic equivalency or bioequivalency, as appropriate, is not adequately
assured.
(b) Pursuant to chapter 91, and subject to the limitations for biological products set forth above in section 328-96(a), the Hawaii additions and deletions list may be changed, added to, or deleted from as the board deems appropriate. Any person who requests that any change be made or that a drug product be included or added to or deleted from the Hawaii additions and deletions list shall have the burden of proof to show cause why the change, inclusion, addition, or deletion should be made.
(c) The board shall revise or supplement the
Hawaii additions and deletions list as necessary[.], subject to the
limitations for biological products set forth above in section 328-96(a).
(d) The department shall provide for
distribution of the Hawaii additions and deletions list and its revisions and
supplements, and the dissemination of notices of changes to the compendia of
therapeutically equivalent generic [drug] drugs and interchangeable
biological products to all pharmacies in the State and to any other
interested individuals. The department may establish fees to be charged to
persons who receive the Hawaii additions and deletions list and its revisions
and supplements, and notices of changes to the compendia of therapeutically
equivalent generic [drug] drugs and interchangeable biological products.
The amounts of the fees charged shall be approximately the same as the costs of
producing and distributing the Hawaii additions and deletions list and its
revisions and supplements, and the notices of changes to the compendia of
therapeutically equivalent generic [drug] drugs and interchangeable
biological products.
(e) Each pharmacy in the State shall:
(1) Maintain and update the compendia of
therapeutically equivalent generic [drug] drugs and interchangeable
biological products as [it is] they are approved by the [director;]
board; and
(2) Obtain the Hawaii additions and deletions list.
(f) The department shall provide for public education regarding the provisions of this part and shall monitor the effects of this part."
SECTION 7. Section 328-97, Hawaii Revised Statutes, is amended to read as follows:
"[[]§328-97[]] Posting
requirements. Every pharmacy shall prominently display, in clear and
unobstructed public view, a sign in block letters [which] that
shall read:
"HAWAII LAW REQUIRES THAT LESS EXPENSIVE GENERICALLY EQUIVALENT DRUG PRODUCTS AND INTERCHANGEABLE BIOLOGICAL PRODUCTS BE OFFERED TO THE CONSUMER. CONSULT YOUR PHYSICIAN AND PHARMACIST CONCERNING THE AVAILABILITY OF THE LEAST EXPENSIVE DRUG PRODUCT FOR YOUR USE."
The letters must be at least one inch in height."
SECTION 8. Section 328-98, Hawaii Revised Statutes, is amended to read as follows:
"§328-98 Pharmacist liability.
A pharmacist who selects [an] a generically equivalent drug
product or an interchangeable biological product pursuant to this part
assumes no greater liability for selecting the dispensed drug product than
would be incurred in filling a prescription for a drug product prescribed by
its established name."
SECTION 9. Statutory material to be repealed is bracketed and stricken. New statutory material is underscored.
SECTION 10. This Act shall take effect upon its approval.
Report Title:
Biosimilar Medicines; Interchangeable Biological Products
Description:
Allows for the dispensing of biosimilar medicines under specified conditions. Regulates interchangeable biological drug products. (HB254 HD1)
The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
